AbbVie (NYSE:ABBV) EVP Jeffrey Ryan Stewart Sells 40,619 Shares of Company Stock

AbbVie Inc. (NYSE:ABBV) EVP Jeffrey Stewart sold 40,619 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the transaction, the executive vice president directly owned 83,171 shares in the company, valued at $24,419,005.60. This trade represents a 32.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

AbbVie Stock Down 0.1%

NYSE ABBV opened at $294.75 on Friday. The stock has a market cap of $521.01 billion, a PE ratio of 50.73, a P/E/G ratio of 1.34 and a beta of 0.20. AbbVie Inc. has a fifty-two week low of $190.75 and a fifty-two week high of $302.93. The business has a 50 day moving average price of $274.82 and a two-hundred day moving average price of $240.55.

AbbVie (NYSE:ABBV) last issued its quarterly earnings data on Friday, October 30th. The company reported $3.82 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.73 by $0.09. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. The company had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. During the same quarter last year, the company earned $1.86 earnings per share. AbbVie’s revenue for the quarter was up 10.3% on a year-over-year basis. Sell-side analysts anticipate that AbbVie Inc. will post 13.98 EPS for the current fiscal year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Investors of record on Friday, January 15th will be paid a dividend of $1.82 per share. This is a positive change from AbbVie’s previous quarterly dividend of $1.73. The ex-dividend date of this dividend is Friday, January 15th. This represents a $7.28 annualized dividend and a yield of 2.5%. AbbVie’s payout ratio is presently 119.10%.

Key Headlines Impacting AbbVie

These are some of the ABBV headlines that stood out recently:

• Positive Sentiment: AbbVie’s immunology sales rose 16.6% in the third quarter, with Skyrizi and Rinvoq growth more than offsetting Humira’s decline. The performance has supported higher 2026 sales expectations and strengthens the case that newer drugs can sustain growth. How Did AbbVie’s Immunology Franchise Fare in Q3?
• Positive Sentiment: AbbVie recently raised its 2026 revenue guidance to about $67.8 billion and increased its dividend after reporting third-quarter revenue of $17.4 billion. These updates reinforce the company’s earnings and shareholder-return outlook. Can AbbVie Justify Its Valuation After Raised Guidance and Strong Results?
• Negative Sentiment: Executive Vice President Jeffrey Stewart sold 40,619 shares for about $11.9 million, reducing his direct holdings by 32.81%. Insider sales can weigh on sentiment, though the filing does not explain the reason for the transaction. SEC Form 4 filing

Wall Street Analysts Forecast Growth

ABBV has been the subject of a number of analyst reports. Wolfe Research raised shares of AbbVie from a “peer perform” rating to an “outperform” rating and upped their price objective for the company from $235.00 to $300.00 in a research report on Thursday, August 13th. Cantor Fitzgerald lifted their target price on AbbVie from $290.00 to $325.00 and gave the stock an “overweight” rating in a research report on Monday, November 2nd. Argus lifted their target price on AbbVie from $250.00 to $270.00 in a research report on Tuesday, August 4th. Erste Group Bank upgraded AbbVie from a “hold” rating to a “buy” rating in a research note on Wednesday, August 5th. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $275.00 price target on shares of AbbVie in a report on Monday, November 2nd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $297.46.

Institutional Trading of AbbVie

A number of hedge funds and other institutional investors have recently made changes to their positions in ABBV. Fisher Asset Management LLC increased its position in shares of AbbVie by 252.6% in the 3rd quarter. Fisher Asset Management LLC now owns 33,489,421 shares of the company’s stock worth $8,760,498,000 after purchasing an additional 23,991,451 shares during the last quarter. Corient Private Wealth LP bought a new position in shares of AbbVie during the second quarter worth about $559,736,000. Legal & General Group Plc acquired a new position in AbbVie in the second quarter worth about $2,905,952,000. Jupiter Topco LLC acquired a new position in AbbVie in the second quarter worth about $1,560,354,000. Finally, Canada Pension Plan Investment Board acquired a new position in AbbVie in the second quarter worth about $817,473,000. Institutional investors own 70.23% of the company’s stock.

AbbVie Company Profile

AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.